Insulet is a tubeless insulin-pump franchise whose second-quarter beat arrived with a guidance cut that recasts the type two expansion as an onboarding problem rather than a demand problem. New starts remain healthy and more than two fifths of United States additions now come from type two patients, yet those users leave therapy inside the first ninety days at a rate management calls meaningful. The equity debate is no longer whether Omnipod can recruit type two patients. It is whether the company can keep them long enough for the Pod refill engine to earn its multiple.
International Omnipod is doing the work the domestic franchise no longer can. Overseas sales reached $252 million. Constant-currency growth was 33%. That run rate was enough for management to lift the full-year international range even as it lowered the domestic one. Adjusted operating margin expanded even while reported operating margin contracted, because two voluntary medical device corrections for cannula tears sat inside cost of revenue. The print therefore splits the franchise into a scaling consumables engine and a retention-and-quality problem the market had not fully priced.
Revenue of $802 million cleared the high end of the company's own constant-currency range. Adjusted diluted earnings were $1.66 per share. Those earnings grew faster than sales. The open question is whether a third-quarter United States Omnipod growth band in the mid-teens, and a preliminary mid-teens exit rate into next year, is a temporary onboarding reset or the new slope of a franchise that used to compound above twenty percent.